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The acquisition of driver mutations in non-tumoral cells appears to be very important during
the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related
mutations may not necessarily be present only in malignant cells, but also in histologically
“healthy cells”.
Objective: to demonstrate the presence of EGFR or KRASmutations in non-tumoral lung
cells in subjects with ADC and negative mutational status.
Results:mutations in EGFR orKRAS oncogenes were identified in the normal lung in 9.7%
of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the
exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS
were detected once. One patient presented three different mutations in the normal lung
parenchyma (EGFR_L858R, KRAS_G12C and KRAS_G12D). The negative-mutation
status of the tumor and the mutations detected in the “normal lung” were confirmed
using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found
in terms of progression, progression-free survival or overall survival during the 18months
follow-up.
Conclusions: These results confirm the presence of driver mutations in the histologically
normal lung parenchyma cells in the absence of mutations coexisting with the
primary tumor.
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INTRODUCTION
Lung cancer, specifically lung adenocarcinoma (ADC), is frequently diagnosed in an advanced stage
with a global 5-years survival not exceeding 17% [1–3]. Even when it is detected at an early stage, the
prognosis is poor, especially in terms of tumor recurrence [4, 5]. Pulmonary ADC has an
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than 75% of the cases. Fortunately, a vast proportion of the
oncogenic driver alterations has potential therapeutic
implications [6]. The acquisition of driver mutations in still
histologically non-tumoral cells appears to be very important
during the ADC carcinogenesis since it will potentially lead to a
clonal cell expansion [7]. Moreover, two studies have
demonstrated the presence of cancer-related mutations in
non-tumoral cells of subjects with endometriosis and
arteriovenous malformations of the brain [8, 9]. These
findings demonstrate that cancer-related mutations may not
necessarily be present only in malignant cells, but also in
histologically non-tumoral cells. Our group has recently
demonstrated that subjects with localized lung ADC with
epidermal growth factor receptor-EGFR or KRAS proto-
oncogene alterations showed the same driver mutation in the
non-tumoral lung tissue as far as a 21.3% of the cases [9]. These
findings were associated with a significantly lower disease-free
survival at 12 months and are in line with other previously
published evidence related with molecular alterations in non-
tumoral lung [10]. Our hypothesis is that cancer-related
mutations can appear in histologically non-cancerous cells
even in the absence of molecular alterations in the primary
tumor during the field cancerization process. Accordingly, the
aim of the present study was to demonstrate the presence of EGFR
or KRAS mutations in non-tumoral lung cells even in subjects
with early-stage ADC with negative mutational testing.
METHODS
Subjects
Subjects with early-stage lung ADC with negative mutational
status and candidates for curative surgical resection were
prospectively recruited in our center, a tertiary teaching
hospital. Tumor and histologically normal lung parenchyma
samples were obtained and processed. Thirty-five subjects with
EGFR mutation-negative and KRAS mutation-negative lung
adenocarcinoma were included. The normal lung parenchyma
(NLP) sample was defined as a histologically normal tissue with
complete absence of micro-tumor invasion assessed by a
pathologist and obtained in the area of the resected lung
furthest from the tumor. Finally, viable non-tumoral DNA was
obtained in 31 of these subjects and a competitive allele-specific
TaqMan PCR was performed to identify the presence of EGFR or
KRAS mutations. The cohort was followed-up during 18 months
and clinical data were collected for months 1, 2, 6, 12 and 18. The
study was designed and carried out in accordance with the ethical
guidelines of the Declaration of Helsinki and European
legislation, and the procedure was approved by our Ethics
Committee. Informed consent was obtained from all individuals.
Tumor DNA Extraction and Sequencing
The molecular study of the tumor was carried out after surgery
and included the detection of EGFR using TheraScreen PCR and
direct sequencing for KRAS alterations. The commercially kit
QIAamp DNA Mini kit (Qiagen, Hilden, Germany) was used for
DNA extraction. The EGFR mutations were detected using the
commercial real-time PCR TheraScreen EGFR RGQ PCR kit
(Qiagen). This is a highly sensitive assay based on Scorpions®
real-time PCR technology and mutation specific ARMS® primers
that detect 29 different somatic mutations in the gene. In
addition, exon 2 of the KRAS gene and exons 18, 19, 20, 21 of
the EGFR gene were studied with Sanger sequencing, using
BigDye v3.1 (Applied Biosystems, Foster City, CA,
United States), being assessed on the 3500DX Genetic
Analyzer (Applied Biosystems).
Normal Lung Parenchyma DNA Extraction
and Sequencing
DNA was extracted from two sections of normal appearing lung
samples using the QIAamp DNAMini kit (Qiagen). Competitive
allele-specific TaqMan PCR (CAST-PCR, Applied Biosystems,
4465804) was performed in order to determine KRAS and EGFR
mutational status. Samples were amplified in duplicate in
independent experiments with TaqMan™ Genotyping Master




and KRAS p.G13C—Hs00000125_mu, EGFR exon 19
deletions—Hs00000228_mu; EGFR p.L858R—Hs00000102_mu;
EGFR p.T790M—Hs00000106_mu and
G719A—Hs00000104_mu. PCR amplifications were performed
in a 7500Fast real-time PCR system (Applied Biosystems). All
experiments have been confirmed and the technique complies
with the Minimum Information for Publication of Quantitative
Real-time PCR Experiments (MIQE).
Statistical Analysis
Categorical variables were described as frequencies and
percentages, whereas continuous variables as mean ± standard
deviation. Pearson’s Chi-Square or Fisher exact tests were used to
compare categorical variables. The non-parametric Mann-
Whitney U test was used to assess differences between groups.
p values ≤0.05 were considered statistically significant. Analyses
were performed with SPSS 21.0.
RESULTS
The main clinical, functional and tumor characteristics of the
cohort are shown in Table 1. All subjects were stratified in stages
based on the present TNM classification (IASLC, 8th edition) and
only stage I or II subjects were included [3]. The surgical
procedures were performed in accordance with the institution
clinical-practice recommendations. The most common
procedure was a lobectomy (67.7%) followed by
segmentectomy (22.6% and bilobectomy (9.7%). Almost all the
subjects (30 of 31, 96.8%) were smokers or former smokers.
We identified five mutations in EGFR or KRAS oncogenes in
the normal lung parenchyma among three subjects (9.7%). The
exon 21 substitution L858R in EGFR was detected in two cases
while the exon 19 deletion E746-A750 in the EGFR, the codon 12
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substitution G12C and G12D in the KRAS were detected once.
Surprisingly, in one patient, three different mutations were
identified in NLP (EGFR_L858R, KRAS_G12C and
KRAS_G12D). More details of the three subjects with mutated
NLP can be found in Table 2.
In these three subjects, the negative-mutation status of the tumor
for the specific mutation detected in the NLP was confirmed using
highly sensitive and specific TaqMan PCR (CAST-PCR). The
confirmation of the positive-mutation status in the NLP was also
performed for the previously mentioned five specific mutations. In
all the assays, the PCR efficiency was between 95 and 105%. To
improve specificity and avoid false positives we only considered as
positives the assays for EGFR mutations when the amplification
occurred before the cycle 35. For the two KRASmutations detected,
the amplification occurred between the cycle 35 and 38. The
mutation was confirmed in both cases. The amplification plots
are shown in Figure 1. Real-time PCR results for positive cases
were confirmed in independent experiments. We have also
performed digital PCR (dPCR) to confirm the presence of the
mutations reported and, in addition, with the samples with
enough material, we have repeated the qPCR assays.
Mutated NLP vs. Non-mutated NLP: Clinical
Outcomes, Recurrence and Survival
We only found differences between both groups in terms of
tobacco status and gender, but considering the limited number of
cases, we cannot draw any conclusion. Data from both groups are
shown in Table 1.
One patient died in the post-operative setting. During the
18 months follow-up, two subjects died within the non-mutated
NLP group, while none died in the other group. No differences
were found in terms of progression (locally or at distance),
progression-free survival or overall survival between both
groups during the follow-up.
DISCUSSION
This study confirms the presence of driver mutations in the
histologically normal lung parenchyma cells coexisting with the
absence of mutations in the primary tumor. Our findings are
consistent with the hypothesis that during the carcinogenesis
process multiple cells can gain somatic mutations without
TABLE 1 | Baseline characteristics and comparison between mutated NLP and non-mutated NLP.
Total n = 31 Mutated NLP n = 3 Non-mutated
NLP n = 28
p value
Age, mean (SD), yrs 64.2 (7.2) 60 (6) 64.5 (7.1) 0.29
Current or former smoker, n (%) 30 (96.8) 2 (66.7) 28 (100) 0.00
Smoking index, mean (SD), pack-year 53.2 (23) 40 (34.6) 54.6 (22) 0.30
Sex, n (%)
Male 25 (81) 1 (33) 24 (86) 0.02
Female 6 (19) 2 (67) 4 (14)
Comorbidities, n (%)
Previous cancer 12 (38.7) 1 (33.3) 11 (39.3) 0.84
Dyslipidemia 10 (32.3) 1 (33.3) 9 (32.1) 0.96
Hypertension 10 (32.3) 0 (0) 10 (35.7) 0.20
Diabetes mellitus 7 (22.6) 1 (33.3) 6 (21.4) 0.63
Alcoholism 9 (29) 0 (0) 9 (32.1) 0.24
COPD 8 (25.8) 0 (0) 8 (28.6) 0.28
Ischemic cardiomyopathy 2 (6.5) 0 (0) 2 (7.1 0.63
Chronic kidney disease 1 (3.2) 0 (00) 1 (3.6) 0.73
Lung function tests, mean (SD)
FEV1, % ref 74.5 (16.1) 81 (31.1) 74.2 (15.3) 0.56
FVC, % ref 86.9 (16.6) 85.5 (28.9) 86.5 (16.1) 0.93
TLC, % ref 99.9 (13) 77 99.8 (13) 0.09
RV/TLC, % 46.2 (11) 38 46.2 (11) 0.47
DLCO, % ref 65.3 (18.8) 79.5 (47) 64.4 (16.4) 0.27
Karnofsky scale, mean (SD) 93.3 (6) 100 92.8 (6) 0.09
Tumor characteristics
SUV By PET, mean (SD), cm 6.5 (4.7) 3.4 (2.5) 6.8 (4.7) 0.33
T (tumor size), mean (SD), cm 2.8 (18.4) 1.4 (0.1) 2.9 (1.8) 0.15
N (nodal infiltration), n (%) 3 (9.7) 1 (33.3) 2 (7.1) 0.14
M (metastasis), n (%) 0 (0) 0 (0) 0 (0) —
Post-operative stage groups, n (%)
I 23 (74.2) 21 (75) 2 (66.7) 0.75
II 8 (25.8) 1 (33.3) 7 (25) 0.75
III - IV 0 (0) 0 (0) 0 (0) —
Diagnostic tests, n (%)
PET-CT scan 27 (87.1) 2 (66.7) 25 (89.2) 0.77
Endobronchial ultrasound (EBUS) 17 (54.8) 2 (66.7) 15 (53.6) 0.76
Abbreviations: NLP, normal lung parenchyma; SD, standard deviation; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital
capacity; TLC, total lung capacity; RV, residual volume; DLco, transfer coefficient for CO; SUV, standardized uptake value; PET, positron emission tomography.
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TABLE 2 | Detailed mutation characteristics and progression.






1 69 M T2AN0M0 KRAS Wild-type NO
EGFR Wild-type
2 67 M T3N1M0 KRAS Wild-type NO
EGFR Wild-type
3 56 M T2AN0M0 KRAS Wild-type YES Adrenal
EGFR Wild-type
4 55 M T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
5 62 M T2AN1M0 KRAS Wild-type YES Lymph Nodes
EGFR Wild-type Local progression
6 58 M T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
7 59 M T1AN0M0 KRAS Wild-type YES Brain
EGFR Wild-type Adrenal
8 67 M T3N0M0 KRAS Wild-type NO
EGFR Wild-type
9 55 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
10 67 M T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
11 55 M T3N0M0 KRAS Wild-type YES Brain
EGFR Wild-type Local progression
12 69 M T2AN0M0 KRAS Wild-type NO
EGFR Wild-type
13 78 M T2AN0M0 KRAS Wild-type NO
EGFR Wild-type
14 75 M T1BN0M0 KRAS Wild-type YES Lymph Nodes
EGFR Wild-type Bones
15 73 M T3N0M0 KRAS Wild-type NO
EGFR Wild-type
16 66 M T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
17 53 F T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
18 60 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
19 60 F T2AN0M0 KRAS Wild-type NO
EGFR Wild-type
20 59 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
21 53 M T1AN0M0 EGFR deletion E746-A750 NO
KRAS Wild-type
22 64 F T1AN0M0 KRAS Gly12Cys YES Liver
KRAS Gly12Asp
EGFR substitution L858R
23 63 F T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
24 72 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
25 68 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
26 61 F T1BN0M0 KRAS Wild-type NO
EGFR Wild-type
27 70 M T1AN0M0 KRAS Wild-type NO
EGFR Wild-type
28 67 M T1AN0M0 KRAS Wild-type YES Lymph Nodes
EGFR Wild-type
29 80 M T2AN0M0 KRAS Wild-type YES Adrenal
EGFR Wild-type
30 65 M T2AN0M0 KRAS Wild-type YES Brain
EGFR Wild-type
31 63 F T1AN0M0 EGFR substitution L858R NO
KRAS Wild-type
Abbreviations: EGFR, Epidermal Growth Factor Receptor gene; KRAS, Kirsten Rat Sarcoma viral oncogene homolog.
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necessarily producing a clonal expansion. In a previous study,
we confirmed that the same driver mutation detected in the
lung adenocarcinoma was also present in non-tumoral
samples in a fifth of the subjects. However, this study has
the limitation that this detection could be secondary to
contamination by tumor DNA from blood or tumor cells,
which may not have been detected by the usual
histopathological methods. Although this limitation was
unlikely, it could not be one hundred percent ruled out. In
the present this study, having excluded the presence of
mutations in EGFR or KRAS by highly specific and sensitive
techniques in the primary tumor, we are able to confirm that
the mutations detected in other lung cells were not the result of
contamination from the tumor. These findings make us change
the way we understand and define a driver-mutation.
The prevalence of EGFR and KRAS mutations detected in
the present study is only 9.7%, lower than the one detected in
our previous study (21.3%) and in those studies on
endometriosis (26%) and arteriovenous malformations of
the brain (48%). The prevalence observed in the present
study is likely to be higher if more extensive molecular
studies that included other molecular alterations were
carried out. Additionally, to stress our ambitious
hypothesis, we decided to increase the specificity not
including the mutations occurred in later cycles of PCR as
well as to exclude the substitution of T790M in exon 20 that
are usually considered as secondary mutations in the final
analysis.
In the present study, we could not find differences in clinical
outcomes such as recurrence or disease-free survival, between the
two groups, possibly because of the sample size. One patient
(33.3%) in the group of the mutated NLP presented progression
at 18 months in the form of hepatic metastases; while in the non-
mutated NLP group 8 (28.6%) did, not reaching however
statistical significance. Subjects in the mutated NLP group
were significantly less-frequent smokers and predominantly
FIGURE 1 | Amplification plots of detected mutations. (A). Amplification plot for EGFR exon 19 deletion E746-A750. (B). Amplification plot for EGFR exon 21
substitution L858R.
Pathology & Oncology Research March 2021 | Volume 27 | Article 5982925
Chalela et al. Non-Tumoral Lung Driver Mutations
women when compared with the non-mutated NLP group, this is
in line with the evidence that is consistent with the higher
prevalence of driver-mutations in non-smoker women.
Interestingly, one patient presented three different mutations
in the NLP sample wich included one in the EGFR and two in the
KRAS. Normally the mutations in EGFR and KRAS are
considered as mutually exclusive mutations in lung cancer.
Although this finding is surprising, it does not seem
improbable either, since, unlike a tumor, where all the cells
come from the clonal expansion of a single malignant cell, the
normal lung parenchyma samples may contain multiple different
cell lines. Our results support our prior hypothesis that molecular
changes can occur in multiple cells even without malignancy
changes.
LIMITATIONS
There are multiple limitations in the present study, mainly the
small sample size, although this limitation does not affect the
main objective of the study, which was to demonstrate the
presence of driver-mutations in the absence of tumor
mutations. The sample size surely affects clinical outcomes,
which was not the objective of the study. Contamination or
sample mix-up of the studied samples with tumor cells that
contain molecular alterations has always been a topic of
discussion, but we consider it highly unlikely for several
reasons. First, by ruling out molecular alterations in the
tumor, contamination would be much less relevant. Second, a
“non-tumoral lung” sample was considered when resection
margins were tumor-free assessed by an expert pathologist and
the area of lung farthest from the tumor was selected for the
molecular analysis.
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